Can an ancient herbal pill improve outcomes after a bleeding stroke?

NCT ID NCT07752719

Not yet recruiting Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This phase 3 trial is testing whether Angong Niuhuang, a traditional Chinese medicine, can improve recovery in people who have had a bleeding stroke (intracerebral hemorrhage). About 1,100 adults who are eligible for non-surgical management will receive either the herbal pill or a placebo, in addition to standard care, starting as soon as possible after the stroke and continuing for 14 days. The main goal is to see if the treatment reduces long-term disability, measured by the modified Rankin Scale, compared to placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Angong Niuhuang pills (ANP), a traditional Chinese medicine, given alongside standard care
What this could lead to: If effective, this could offer a new, widely accessible add-on treatment to improve functional recovery and reduce disability after a bleeding stroke.
What could go wrong: This is a large trial, but the treatment is an unproven traditional remedy; it may not outperform placebo, and there are risks of adverse effects or interactions with standard stroke care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTRACEREBRAL HEMORRHAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

intracerebral hemorrhage stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTRACEREBRAL HEMORRHAGE STROKE

More trials for these conditions

Other studies related to the condition(s) this trial covers.